Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
暂无分享,去创建一个
P. Opolon | Hong Li | J. Soria | C. Legrand | C. Soria | M. Perricaudet | He Lu | D. Belin | P. Yeh | J. Vannier | F. Griscelli
[1] D. Cines,et al. Integrin (cid:1) M (cid:2) 2 Orchestrates and Accelerates Plasminogen Activation and Fibrinolysis by Neutrophils* , 2022 .
[2] Soo-Ik Chang,et al. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain , 2003, Experimental & Molecular Medicine.
[3] M. Perricaudet,et al. In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy , 2003, Gene Therapy.
[4] A. Mazar,et al. The kringle stabilizes urokinase binding to the urokinase receptor. , 2003, Blood.
[5] R. Béliveau,et al. Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration. , 2003, Blood.
[6] A. Krüger,et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. , 2003, Current pharmaceutical design.
[7] Soo-Young Lee,et al. Anti-angiogenic Activity of the Recombinant Kringle Domain of Urokinase and Its Specific Entry into Endothelial Cells* , 2003, The Journal of Biological Chemistry.
[8] E. Plow,et al. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration. , 2003, Blood.
[9] P. Carmeliet,et al. uPAR: a versatile signalling orchestrator , 2002, Nature Reviews Molecular Cell Biology.
[10] D. V. van Bekkum,et al. Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth , 2002, BMC Cancer.
[11] V. Tkachuk,et al. The Chemotactic Action of Urokinase on Smooth Muscle Cells Is Dependent on Its Kringle Domain , 2000, The Journal of Biological Chemistry.
[12] P. Opolon,et al. Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. , 1999, Human gene therapy.
[13] P. Opolon,et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice , 1998, Gene Therapy.
[14] P. Quax,et al. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[15] P. Carmeliet,et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation , 1997, Nature Genetics.
[16] S. Rosenberg,et al. 168 Structure function studies on the urokinase receptor: Urokinase system. Murine-human hybrid proteins define critical regions for species specificity , 1997 .
[17] Y. Wei,et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. , 1997, The Journal of clinical investigation.
[18] Y. Kook,et al. Co‐expression of urokinase‐type plasminogen activator and its receptor in human gastric‐cancer cell lines correlates with their invasiveness and tumorigenicity , 1997, International journal of cancer.
[19] F. Bayard,et al. Extracellular Cleavage of the Vascular Endothelial Growth Factor 189-Amino Acid Form by Urokinase Is Required for Its Mitogenic Effect* , 1997, The Journal of Biological Chemistry.
[20] L. Zanetta,et al. Control of type IV collagenase activity by components of the urokinase–plasmin system: a regulatory mechanism with cell‐bound reactants , 1997, The EMBO journal.
[21] C. Zandonella,et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. , 1996, Cancer research.
[22] U. Weidle,et al. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. , 1996, European journal of biochemistry.
[23] V. V. van Hinsbergh,et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity , 1996, The Journal of cell biology.
[24] Hong Li,et al. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells , 1996, FEBS letters.
[25] J. Foekens,et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. , 1995, Journal of the National Cancer Institute.
[26] J. Soria,et al. Blockage of the urokinase receptor on the cell surface: Construction and characterization of a hybrid protein consisting of the N‐terminal fragment of human urokinase and human albumin , 1994, FEBS letters.
[27] J. Bruner,et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. , 1994, Cancer research.
[28] T. Terao,et al. Inhibition of metastasis of lewis lung carcinoma by a synthetic peptide within growth factor‐like domain of urokinase in the experimental and spontaneous metastasis model , 1994, International journal of cancer.
[29] L. Orci,et al. Upregulation of urokinase receptor expression on migrating endothelial cells , 1993, The Journal of cell biology.
[30] T. Terao,et al. Increased Cell‐surface Urokinase in Advanced Ovarian Cancer , 1993, Japanese journal of cancer research : Gann.
[31] A. Levinson,et al. Prevention of metastasis by inhibition of the urokinase receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[32] W. Birchmeier,et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. , 1992, The EMBO journal.
[33] E. Keshet,et al. In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[34] M. Perricaudet,et al. Widespread long-term gene transfer to mouse skeletal muscles and heart. , 1992, The Journal of clinical investigation.
[35] K. Danø,et al. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.
[36] F. Blasi,et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.
[37] F. Blasi,et al. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. , 1991, The Journal of biological chemistry.
[38] P. Dennis,et al. Growth factor control of extracellular proteolysis. , 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.
[39] L. Orci,et al. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.
[40] A. Vaheri,et al. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants , 1989, The Journal of cell biology.
[41] A. Eisen,et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[42] D. Belin,et al. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. , 1987, Cancer research.
[43] E. Appella,et al. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. , 1987, The Journal of biological chemistry.
[44] R. Duvoisin,et al. Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator. , 1985, European journal of biochemistry.
[45] D. Rifkin,et al. Biology and biochemistry of proteinases in tumor invasion. , 1993, Physiological reviews.
[46] A. Maseri,et al. Age Dependence of Ischaemic Heart Syndromes and the Contribution of Haemostatic Deviations , 1992 .